fair enough - I think manufacturing shouldn’t be an issue. It clearly has the advantage in that area. I think it’s more the logistics and supply chain of the drug that will make it tricky to commercialise. It has a longer half life but it is still time sensitive.
Personally, it’s not something that I know too much about but that would definitely be something Pharma companies will look for as well as the manufacturing.
Research/Valuation, page-5
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.53 |
Change
-0.070(2.69%) |
Mkt cap ! $775.5M | |||
| Open | High | Low | Value | Volume |
| $2.59 | $2.60 | $2.53 | $652.8K | 256.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 200 | $2.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.59 | 14109 | 2 |
View Market Depth
| Last trade - 16.10pm 26/04/2024 (20 minute delay) ? |
|
|||||
|
Last
$2.53 |
Change
-0.070 ( 2.40 %) |
||||
| Open | High | Low | Volume | ||
| $2.58 | $2.60 | $2.53 | 29022 | ||
| Last updated 15.59pm 26/04/2024 ? | |||||
| CU6 (ASX) Chart |